drugset / Trial / NCT00701493

A Phase 1 Bioavailability Study of Topiramate Oral Liquid Formulation Compared to the Marketed Sprinkle Capsule Formulation in Healthy Adults

NCT00701493

RandomizedCrossoverOpen-labelTreatment

Summary

The primary purpose of this study is to estimate the bioavailability of the oral liquid formulation of topiramate relative to the commercially available oral sprinkle capsule formulation in healthy patients. If appropriate, bioequivalence between the oral liquid formulation and the sprinkle capsule formulation will be assessed.

Timeline

Start
2004-11
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 100 mg Oral

Indications